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HIV RNA load and opportunistic infections 
Clin Microbiol Infect 1997; 3: 501 
Many researchers consider that the HIV viral load assay 
is a useful marker for disease progression in HIV- 
infected patients treated with antiviral drugs. O n  the 
other hand, the conclusions of a recent Food and Drug 
Administration (FDA)-sponsored meeting [1] were 
that, in the design of clinical trials of anti-HIV drugs, 
there is a lack ofvalid clinical and immunologic criteria. 
To clarify the interrelation between viral replication and 
disease progression, we have carried out an initial study 
of the HIV KNA load (determined by the Amplicor 
Koche System) and its correlation with CD4 cells at  
different times of HIV disease in the same patients with 
HIV disease. 
Seven HIV-positive patients, sex and age matched, 
with a CD4 cell counts < 100 110 mm3, who had been 
treated with zidovudine (250 mg twice daily) plus 
zalcitabine (0.75 mg three times daily) for at  least 6 
months, were evaluated prospectively. At the time of 
enrolment (after 6 or more months of therapy), a 
definite diagnosis of neurotoxoplasmosis had been 
made. HIV R N A  load and CD4 cell count were 
determined before and 3 weeks after specific therapy 
(sulfadiazine, 1 g four times daily, and pyriniethamine 
25 mg twice daily) was started. As reported in Table 1, 
our data showed a significant difference (p<O.001 by 
means of linear regression) in HIV load between the 
patients at the time of the neurotoxoplasmosis and after 
3 weeks’ treatment, and no correlation between CD4 
cell count and HIV load at the two times of estimation. 
There was no significant difference in CD4 cell counts 
( ~ 0 . 9 3 0 ;  p’0.002) on the two occasions. 
Various inferences can be drawn from these results. 
Neurotoxoplasmosis may induce immune activation of 
latently infected cells, as reported by others [Z], and 
Table 1 HIV R N A  load and CD4 cell count at the time 
of neurotoxoplasmosis (baseline) and after 3 weeks of 
antitoxoplasnia treatment 
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this may being about a transient increase in viral load. 
The plasma viral load appears to be unrelated to the rate 
of CD4+ T-cell destruction. In spite of continuous 
antiviral treatment, the viral load may increase during 
opportunistic infections. These data cast doubt on the 
use of the measurement of HIV load in the plasma to 
evaluate HIV progression, particularly in patients in the 
advanced stages of HIV infection. We think it possible 
that plasma viral load is a direct reflection of viral 
replication modified by different factors as mentioned 
above. It seems that the measurement of CD4 cell 
count remains the single best means of documenting 
HIV progression. 
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Cytomegalovirus seminal shedding in healthy volunteer 
sperm donors 
Clin Micvobiol Infect 1997; 3: 501-503 
Cytomegalovirus (CMV) commonly infects humans 
throughout the world. After the primary infection, the 
virus remains in a latent state in the host. In clinically 
healthy individuals, reactivation of latent virus frequently 
results in asymptoniatic excretion of CMV; the virus 
may be excreted in genital secretions and sexually 
transmitted 111. CMV may cause severe congenital 
disease when a primary infection occurs during the 
course of pregnancy. A less severe congenital infection 
may also result from a secondary maternal infection [2] 
due to reactivation of the latent virus or infection with 
a new viral strain [3]. O n  the other hand, direct 
contamination of the fetus is theoretically possible 
through germ cells and spermatozoa [4]. Therefore, 
semen samples collected from CMV-seropositive sperm 
donors constitute a possible source of CMV infection 
for women involved in a therapeutic donor insernina- 
tion (TDI) and may bring about a congenital CMV 
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disease in their offspring. For this reason, the British 
Andrology Society and the American Fertility Society 
[5] recommend the determination of sperm donors' 
serologic status by a CMV-specific immunoglobulin G 
(IgG) test, and the use of semen specimens obtained 
from CMV-seropositive donors only for seropositive 
recipients. In France the legislation is more restrictive, 
as the sperm specimens collected from CMV-sero- 
positive donors (50-70'%, of the donor population) are 
excluded from TDI. 
With the aim of evaluating the frequency of CMV 
shedding in sperm donors and thus assessing the risk 
of CMV transmission through TDI, we investigated 
retrospectively the presence of CMV in semen samples 
collected in two French sperm banks between March 
1986 and November 1994. One hundred and thirty- 
eight semen samples collected from 76 healthy, unpaid, 
candidate sperm donors who had previously fathered at  
least one child were analyzed, cryopreserved in liquid 
nitrogen and tested for the presence of CMV by shell 
vial culture [6]. Briefly, semen was diluted 1 : l O  in 
Eagle's minimum essential medium (EMEM) supple- 
mented with 2% fetal calf serum (FCS) and then 
inoculated onto MRC-5 cell monolayers in 24-well 
tissue culture plates. Plates were centrifuged at 980s 
for 45 min at 37°C. After removal of the inoculum 
and addition of EMEM 2% FCS into wells, plates 
were incubated for 18 h at 37°C. The CMV major 
immediate early antigen in monolayers was detected by 
an immunoperoxidase assay with the monoclonal anti- 
body E l 3  (Arghe, Varilhes, France). 
Twenty-two (28.9%) donors were CMV sero- 
negative, 42 (55.3%) were CMV seropositive, and the 
remaining 12 (15.8%) had an unknown serologic status. 
All the 64 donors tested for CMV-specific antibodies 
were negative for IgM. CMV was detected in five 
(3.6%) samples from two (4.8%) CMV-seropositive 
donors. 
CMV has been frequently detected in semen 
specimens from HIV-1-infected individuals [7,8]. 
CMV shedding in semen has also been investigated 
in men seeking fertility evaluation but discrepant 
results have been reported [9,10]. In Germany, CMV 
DNA was not detected by dot blot in the semen 
samples collected from 63 subjects. In contrast, a study 
conducted in Taiwan reported detection of CMV 
DNA by polymerase chain reaction (PCR) in 71 of217 
semen samples. Differences in the CMV prevalence 
between the two studied populations, and the use of 
different detection procedures, might explain these 
discrepancies. Studies on CMV shedding in semen 
collected from clinically healthy volunteer donors have 
not been reported until now. Our results establish the 
presence of CMV in cryopreserved semen specimens 
collected from healthy donors for TDI. Furthermore, 
CMV isolation by cell culture demonstrates their 
infectious character. We can therefore conclude that 
the semen of clinically healthy volunteer donors is a 
possible source of CMV infection and a potential cause 
of congenital CMV disease. 
CMV antibodies, which only represent a marker 
of past CMV infection, cannot predict CMV seminal 
shedding, since only a small proportion of CMV- 
seropositive donors excrete CMV in semen at the time 
of donation (less than 5.0% in the present study). 
O n  the other hand, CMV antibody tests are not 
100% sensitive. Consequently, CMV-specific antibody 
detection cannot completely remove the risk of CMV 
shedding in semen. Therefore, direct identification of 
CMV in semen specimens could be considered a more 
appropriate method than antibody testing to exclude 
the potentially infectious specimens. Moreover, taking 
into consideration the risk of reinfection in CMV- 
seropositive recipients, the semen specimens found 
positive for CMV should be excluded from TDI, 
whatever the serologic status of the recipient. It is now 
well established that P C R  is much more sensitive than 
cell culture in detecting CMV in clinical specimens 
[11,12]. By the use of primers located in conserved 
regions of the CMV genome, small amounts of DNA 
from all strains can be detected. P C R  could then 
constitute a promising procedure to select CMV-free 
semen samples for TDI. However, the relevance of 
this strategy remains to be evaluated. Therefore, 
detection of CMV DNA by P C R  in all the semen 
samples collected in our sperm banks is now being 
developed. 
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In vitro activity of antibiotics and combinations against 
Brucella melitensis 
Clin Mic-vobiol h f i c t  1997; 3: 503-506 
Brucellosis is distributed worldwide and remains 
endemic in many parts of the developed world [I]. The 
treatment of brucellosis requires combined regimens of 
antibiotics and is conditioned by the fact that brucellae 
are intracellular pathogens; thus, agents with a good 
capacity to penetrate macrophages are required for 
successful treatment. The regimen recommended for 
the treatment of brucellosis is a combination of oral 
tetracycline and intramuscular streptomycin. Another 
regimen used is doxycycline (DOX) plus rifampin 
W F )  1231. 
Ciprofloxacin (CIP) and other quinolones have 
been shown to be active in vitro against Brrirella 
melitensis [4]. Azithromycin (AZI) is a 1 5-membered 
ring azalide antibiotic. In view of the excellent levels 
attained by the quinolones and AZI within the 
macrophage, these agents could be useful alternatives in 
the treatment of brucellosis [5]. The purpose of this 
study was to determine the in vitro activity of KIF, 
DOX, CIP and AZI against B. rizelitensis clinical isolates 
and to investigate the in vitro activity of combinations 
such as DOX-CIP, CIP-KIF, DOX-RIF, RIF-AZI 
and DOX-AZI against €3. melitenris. 
The 42 B. rielitensic strains studied were clinical 
isolates from patients with brucellosis at the Erciyes 
University Hospital (Kayseri, Turkey). All strains were 
maintained as frozen stocks (-70°C) and twice sub- 
cultured before starting the studies.The antibiotics 
evaluated in this study were obtained from their 
manufacturers as laboratory powder (RIF, Lepetit-Sifar, 
Turkey; DOX, Fako, Turkey; CI? Eczaclbqi, Turkey; 
AZI, Pfizer, Turkey). 
MICs were determined by the agar dilution 
technique using Mueller-Hinton agar (Oxoid, UK) as 
recommended by the National Committee for Clinical 
Laboratory Standards [6]. The range of concentrations 
was from 128 to 0.015 pg/mL for all the antibiotics 
tested. Inocula were prepared by making a suspension 
of B. melitensis colonies from subcultures on Bnrcella 
agar (Oxoid, UK) into Mueller-Hinton broth (Oxoid, 
UK). Plates of Mueller-Hinton agar were inoculated 
with approximately 104-105 colony-forming units 
(CFUs) per spot. Control strains (Staphylococcus aweus 
ATCC 29213 and Esclzericliia ndi ATCC 25922) were 
included in all studies. Plates of Mueller-Hinton agar 
without antibiotic were used as controls. Plates were 
incubated at 35°C for 48 h, and the MlCs were 
determined. The MICs were defined as the lowest 
concentrations of antibiotics that prevented visible 
growth on the agar surface. 
The activities of the DOX-CIP, CIP-KIF, 
DOX-RIF, RIF-AZI and DOX-AZI combinations 
were determined by a two-diniensional checkerboard 
agar dilution method [7]. The concentrations tested 
for each antibiotic typically ranged from four to five 
dilutions below the MIC to two dilutions above the 
MIC, using two-fold dilutions of each antibiotic in 
Mueller-Hinton agar. One of the antibiotics was diluted 
along the abscissa and the other along the ordinate, 
thereby providing all possible two-fold combinations of 
the antibiotic concentrations. Plates were inoculated 
and MICs were determined after incubation as described 
above. 
